StreetInsider.com News Articles

Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update

Fri, 28 Aug 2026 17:01:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated.

Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our H1 financial results show our continued investment in research and development programs, mainly our GBA1, Niemann Pick C and Progranulin programs. Spending during the period was lower than H1 2025 because our work on selecting superior

Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update

Fri, 28 Aug 2026 17:01:00 -0400

Sharp Therapeutics closes C$1.37M non-brokered private placement

Wed, 29 Jul 2026 08:46:07 -0400

Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has closed a non-brokered private placement, raising aggregate gross proceeds of C$1,365,000 through the issuance of 1,500,000 common shares at C$0.91 per share, according to a press release statement.

The net proceeds will be used for general working capital purposes.

Newlin Investment Company 1, LLC, an entity wholly owned by William R. Newlin, participated in the offering for US$200,000.45. Newlin serves as a director and Chairman of the company and is considered an insider, making his participation a related-party transaction under Multilateral Instrument 61-101.

The company said it is exempt from requirements to obtain a formal

Sharp Therapeutics Announces Closing of Non-Brokered Private Placement

Wed, 29 Jul 2026 08:45:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement (the "Offering") of common shares in the capital of the Company (the "Common Shares") for aggregate gross proceeds of C$1,365,000 through the issuance of 1,500,000 Common Shares at a price of C$0.91 per Common Share. The net proceeds of the Offering will be used for general working capital purposes.

Newlin Investment Company 1, LLC, an entity wholly owned by William R. Newlin, subscribed for

Sharp Therapeutics Announces Closing of Non-Brokered Private Placement

Wed, 29 Jul 2026 08:45:00 -0400

Newlin Investment Company 1, LLC, an entity wholly owned by William R. Newlin, subscribed for

Sharp Therapeutics plans C$1.37M private placement, drops US$10M deal

Wed, 15 Jul 2026 08:02:38 -0400

Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) announced a non-brokered private placement to raise gross proceeds of up to C$1,365,000, with common shares priced at no less than C$0.91 per share. The company expects the offering to close in the third quarter of 2026, with net proceeds earmarked for general working capital.

Newlin Investment Company 1, LLC, an entity wholly owned by William R. Newlin, the company's director and chairman, intends to subscribe for approximately US$200,000 under the same terms as other participants. The insider participation constitutes a related-party transaction under Multilateral Instrument 61-101, though the company says it qualifies for

Sharp Therapeutics plans C$1.37M private placement, drops US$10M deal

Wed, 15 Jul 2026 08:02:38 -0400

Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update

Wed, 15 Jul 2026 08:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of up to C$1,365,000 (the "Offering"). The Offering will consist of common shares in the capital of the Company (the "Common Shares") priced at not less than C$0.91 per Common Share. The Company expects the Offering to close in Q3 2026. The net proceeds of the Offering will be used for general working capital purposes.

Newlin Investment Company 1, LLC, an entity wholly

Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update

Wed, 15 Jul 2026 08:00:00 -0400

Newlin Investment Company 1, LLC, an entity wholly

Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Tue, 30 Jun 2026 17:00:00 -0400

Shareholders Must Recast Their Votes to be Counted

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026.

The Company has filed an amended and restated notice of meeting (the "Amended and Restated NOM") and an amended and restated management information circular for the Meeting (the "Amended and Restated Circular") in order to give notice and disclosure

Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Tue, 30 Jun 2026 17:00:00 -0400

Shareholders Must Recast Their Votes to be Counted

Sharp Therapeutics reports cholesterol reduction in rare disease study

Thu, 28 May 2026 16:00:26 -0400

Sharp Therapeutics Corp. (TSX-V: SHRX) (OTCQB: SHRXF) announced preclinical data showing its small-molecule compounds reduced cholesterol accumulation in cells from patients with Niemann-Pick disease type C. The company presented the findings at a scientific conference in Tucson, Arizona.

The biotechnology company used its Disco small-molecule discovery platform to identify compounds that reduced intracellular free cholesterol accumulation in primary fibroblast cells from NPC patients at sub-micromolar concentrations. The compounds also increased lysosomal exocytosis and reversed mTOR pathway hyperactivation in patient cells.

"Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support

Sharp Therapeutics reports cholesterol reduction in rare disease study

Thu, 28 May 2026 16:00:26 -0400

"Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support

Sharp Therapeutics reports cholesterol reduction in rare disease study

Thu, 28 May 2026 16:00:26 -0400

"Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support

Sharp Therapeutics reports cholesterol reduction in rare disease study

Thu, 28 May 2026 16:00:26 -0400

"Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support

Sharp Therapeutics reports cholesterol reduction in rare disease study

Thu, 28 May 2026 16:00:26 -0400

"Our lead chemical series significantly reduced the cholesterol accumulation central to NPC pathology, while additional lysosomal exocytosis and mTOR signaling data support

Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C